tiprankstipranks
Trending News
More News >

BioVie Announces 1-for-10 Reverse Stock Split

Story Highlights
BioVie Announces 1-for-10 Reverse Stock Split

Don’t Miss TipRanks’ Half-Year Sale

BioVie ( (BIVI) ) has issued an update.

On June 23, 2025, BioVie Inc.’s stockholders approved a reverse stock split of its Class A common stock, allowing the board to consolidate shares at a ratio between 1-for-5 and 1-for-10. On June 26, 2025, the board decided on a 1-for-10 reverse stock split, effective July 7, 2025, which will adjust the trading of shares on The Nasdaq Capital Market and affect stock options and warrants proportionately.

The most recent analyst rating on (BIVI) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on BioVie stock, see the BIVI Stock Forecast page.

Spark’s Take on BIVI Stock

According to Spark, TipRanks’ AI Analyst, BIVI is a Underperform.

BioVie faces significant financial challenges as it remains in the R&D phase with no revenue. The strong equity position offers some balance sheet support, but high cash burn and reliance on external financing are concerns. Technical indicators show bearish momentum, and valuation metrics reflect typical pre-revenue biotech risks. Overall, the stock is rated poorly due to these combined factors.

To see Spark’s full report on BIVI stock, click here.

More about BioVie

Average Trading Volume: 422,607

Technical Sentiment Signal: Strong Sell

Current Market Cap: $19.13M

For an in-depth examination of BIVI stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1